Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18278379 | BINDING-TRIGGERED REGULATION OF PROTEIN DEGRADATION | Non-Final OA | The Regents of the University of California |
| 17820418 | CROSS-REACTIVE ANTIBODIES AND USES THEREOF | Final Rejection | VANDERBILT UNIVERSITY |
| 18255094 | COMBINATIONS OF SMALL MOLECULE DRUG CONJUGATE AND CAR-EXPRESSING CYTOTOXIC LYMPHOCYTES AND METHODS OF TREATING CANCER USING THE SAME | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 17772865 | METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3 | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 17780389 | ANTIBODIES AGAINST PD-L1 AND METHODS OF USE THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18548481 | TARGETING T REGULATORY CELLS TO ISLET CELLS TO STALL OR REVERSE TYPE 1 DIABETES | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17627975 | SELF-ASSEMBLED VACCINES AND COMBINATION THERAPIES FOR TREATING CANCER | Final Rejection | The General Hospital Corporation |
| 18284413 | CAR T CELL THERAPY AND IFN GAMMA | Non-Final OA | CITY OF HOPE |
| 18284952 | THERAPEUTIC INHIBITORS OF GDF15 SIGNALLING | Non-Final OA | KYMAB LIMITED |
| 18284487 | COMPOSITIONS AND METHODS FOR CELL-BASED DELIVERY SYSTEMS | Non-Final OA | Shriners Hospitals for Children |
| 18284275 | FUSION PROTEINS AND USES THEREOF | Non-Final OA | Legend Biotech USA Inc. |
| 18368516 | CHIMERIC ANTIGEN RECEPTOR AND CELL INCLUDING CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | ARCE THERAPEUTICS, INC. |
| 18367728 | METHODS OF PRODUCING MIXED CHIMERISM AFTER A SOLID ORGAN TRANSPLANT | Non-Final OA | MEDEOR THERAPEUTICS, INC. |
| 18550006 | METHODS OF ENHANCING DIVERSITY OF HLA HAPLOTYPE EXPRESSION IN TUMORS TO BROADEN TUMOR CELL SUSCEPTIBILITY TO TCR-T THERAPY | Non-Final OA | T-Cure Bioscience, Inc. |
| 17635490 | MULTIMERIC BISPECIFIC ANTI-CD123 BINDING MOLECULES AND USES THEREOF | Non-Final OA | IGM Biosciences, Inc. |
| 18278639 | CO-EXPRESSED CXCR2 AND T CELLS OF STAR SPECIFIC TO GPC3, AND USE THEREOF | Non-Final OA | (SHANGHAI ICELL BIOTECHNOLOGY CO., LTD.) |
| 18260214 | ANTI-PD-1/CD47 BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | ABVISION, INC. |
| 18306927 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY | Non-Final OA | PACT PHARMA, INC. |
| 17912789 | HIGH-AFFINITY TCR FOR RECOGNIZING AFP ANTIGEN | Non-Final OA | XLIFESC, LTD. |
| 17640598 | ANTI-STEAP1 ANTIBODIES AND USES THEREOF | Final Rejection | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18250156 | CHIMERIC ACTIVATION RECEPTORS | Non-Final OA | Lyell Immunopharma, Inc. |
| 18043675 | ANTI ABCC1 ANTIBODIES AND USES THEREOF | Non-Final OA | William Robert Arathoon living Trust Dated August 29, 2016 |
| 18042927 | NUCLEIC ACID CONSTRUCTS FOR EXPRESSING POLYPEPTIDES IN CELLS | Non-Final OA | QUELL THERAPEUTICS LIMITED |
| 18005833 | ANTIBODIES AGAINST LEFTY PROTEINS | Non-Final OA | Onena Medicines, S.L. |
| 17911678 | A TARGETING MODULE COMPRISING PD-L1 AND/OR PD-L2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR MEDIATED IMMUNE RESPONSE IN A MAMMAL | Final Rejection | AvenCell Europe GmbH |
| 17769544 | OX40/PD-L1 BISPECIFIC ANTIBODY | Non-Final OA | JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD. |
| 17639237 | ENGINEERED HUMAN IMMUNE CELLS, PREPARATION METHOD AND APPLICATION THEREOF | Final Rejection | ZHAOTAI IMMUGENE BIOMEDICINE (HONG KONG) LIMITED |
| 17631170 | METHODS FOR TREATING SOLID TUMORS | Non-Final OA | Breakbio Corp. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy